Commutee

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

March 21, 2019 by  
Filed under News

Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer’s disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday.


Source: Reuters Business News

Comments are closed.